Marijuana Business Daily has reported that 28 members of Congress have filed a brief to go along with the pending lawsuit against the DEA for keeping cannabidiol (CBD) a schedule 1 drug. The 9th Circuit Court of Appeals is set to hear arguments February 15th. The Congress members argue...
The World Health Organization (WHO), which is an agency of the United Nations (UN), and looked to as the navigator for many health organizations worldwide, has endorsed a recommendation from the Expert Committee on Drug Dependence (ECDD) that cannabidiol (CBD) based on the current information does not justify scheduling and...
Cannabidiol is a safe, non-intoxicating, and non-addictive cannabis compound with significant therapeutic attributes, but CBD-drug interactions may be problematic in some cases. CBD can potentially interact with many pharmaceuticals by inhibiting the activity of cytochrome P450, a family of liver enzymes. This enzyme group metabolizes most of the drugs we use....
As far back as 2015, Leafly, reported on the topic of CBD and drug testing. According to their research, the urine drug screen for THC is known to have very little cross-reactivity to other cannabinoids that are not psychoactive, such as CBD(cannabidiol). This is good news for “normal” consumers of...